SCHEMBL24430074

SCHEMBL24430074

Cc1ccc(N2C(=O)C=C(Nc3cc(F)c(O)c(F)c3)C2=O)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.50
▸ KMT2A Q03164 2/20 0.50
▸ ALDH1A1 P00352 4/20 0.38
▸ POLB P06746 2/20 0.38
▸ HPGD P15428 1/20 0.38
▸ KDM4E B2RXH2 2/20 0.37
▸ MGLL Q99685 1/20 0.37
▸ F2 P00734 1/20 0.36
▸ ELANE P08246 1/20 0.36
▸ CTSG P08311 1/20 0.36
▸ CMA1 P23946 1/20 0.36
▸ CTRC Q99895 1/20 0.36
▸ GAA P10253 1/20 0.35
▸ G6PD P11413 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ CA9 Q16790 2/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ CASP1 P29466 1/20 0.34
▸ RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26205918 0.91 MEN1 (0.51) MEN1KMT2AALDH1A1POLBHPGD
SCHEMBL24430113 0.91 MEN1 (0.54) MEN1KMT2AALDH1A1POLBHPGD
SCHEMBL26205855 0.90 MEN1 (0.52) MEN1KMT2AALDH1A1POLBHPGD
SCHEMBL24430026 0.90 KMT2A (0.52) MEN1KMT2AALDH1A1POLBKDM4E
SCHEMBL24430002 0.88 MEN1 (0.48) MEN1KMT2AALDH1A1KDM4EGAA
SCHEMBL24430075 0.88 KMT2A (0.45) MEN1KMT2AALDH1A1POLBHPGD
SCHEMBL24430114 0.87 MEN1 (0.68) MEN1KMT2AALDH1A1KDM4EMGLL
SCHEMBL24430013 0.87 MEN1 (0.49) MEN1KMT2AALDH1A1POLBHPGD
SCHEMBL24430078 0.86 MEN1 (0.50) MEN1KMT2AALDH1A1KDM4EMGLL
SCHEMBL24429999 0.86 KMT2A (0.47) MEN1KMT2AALDH1A1KDM4ECA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230339860-A1 Compounds for the Treatment Of Acute and Chronic Kidney Disease SOUTHERN RES INST (US) 2023-10-26 — — US disclosed
US-11753374-B2 Compounds for the treatment of acute and chronic kidney disease Southern Reserach Institute (US) 2023-09-12 — — US disclosed
US-11753374-B2 Compounds for the treatment of acute and chronic kidney disease Southern Reserach Institute (US) 2023-09-12 — — US disclosed
WO-2022109067-A1 COMPOUNDS FOR THE TREATMENT OF ACUTE AND CHRONIC KIDNEY DISEASE SOUTHERN RESEARCH INSTITUTE (US) 2022-05-27 — — WO disclosed
WO-2022109066-A1 COMPOUNDS FOR THE TREATMENT OF ACUTE AND CHRONIC KIDNEY DISEASE SOUTHERN RESEARCH INSTITUTE (US) 2022-05-27 — — WO disclosed
US-20220153702-A1 Compounds for the Treatment Of Acute and Chronic Kidney Disease UAB RESEARCH FOUNDATION 2022-05-19 — — US disclosed
US-20220153695-A1 Compounds for the Treatment Of Acute and Chronic Kidney Disease THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS 2022-05-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220153695-A1 Compounds for the Treatment Of Acute and Chronic Kidney Disease HMOX1, GLS, HMOX2 MEN1 4171/4885KMT2A 2088/4885ALDH1A1 703/4885
US-20220153702-A1 Compounds for the Treatment Of Acute and Chronic Kidney Disease HMOX1, HMOX2, GLS MEN1 4651/4885KMT2A 2904/4885ALDH1A1 671/4885
US-20230339860-A1 Compounds for the Treatment Of Acute and Chronic Kidney Disease HMOX1, HMOX2, GLS MEN1 4651/4885KMT2A 2904/4885ALDH1A1 671/4885
US-11753374-B2 Compounds for the treatment of acute and chronic kidney disease HMOX1, GLS, HMOX2 MEN1 4171/4885KMT2A 2088/4885ALDH1A1 703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback